GBLX - GB Sciences launches preclinical studies with cannabinoid compositions

GB Sciences ([[GBLX]] +13.3%) in collaboration with Michigan State University, has initiated the proof-of-concept data to support the use of their new proprietary cannabinoid containing complex mixtures ((CCCM)) for the treatment of Cytokine Release Syndrome and associated hyperinflammatory conditions such as macrophage activation syndrome and acute respiratory distress syndrome in COVID-19 patients.The company says CCCM are designed to reduce specific cytokines and pro-inflammatory processes triggered by SARS-CoV-2 infections, while preserving those immune functions and cytokines that are necessary for fighting the viral infection.The company filed provisional patent application for the use of its CCCM for the treatment of cytokine storm syndromes, last year in August.

For further details see:

GB Sciences launches preclinical studies with cannabinoid compositions